Gilead Sciences, Inc.
NEWS
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
In the 5-day remdesivir group, patients were 65% more likely to see clinical improvement at 11 days compared to those treated with standard-of-care only.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
“As more information about COVID-19 pneumonia becomes available in these unprecedented times, it is more important than ever to work together to fight this disease,” said Levi Garraway, Roche’s chief medical officer and head of Global Product Development.
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’s pipeline products.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
JOBS
IN THE PRESS